Price Chart

Headline
Wire
Time (ET)
DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
01/27/2023* -- Results Q4 2022 -- -0.80 --
10/06/2022 -- Results Q3 2022 -0.90 -0.95 5.05%
07/07/2022 -- Results Q2 2022 -1.01 -0.99 -2.17%
04/08/2022 -- Results Q1 2022 -0.95 -0.89 -7.04%
01/27/2022 -- Results Q4 2021 -0.85 -0.70 -22.06%
10/14/2021 -- Results Q3 2021 -0.65 -0.62 -4.53%
07/13/2021 -- Results Q2 2021 -0.60 -0.56 -7.53%
04/13/2021 -- Results Q1 2021 -0.63 -0.45 -38.88%
*Estimated Date/Time

Earnings

Next Report Date 01/27/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 10/06/2022
Beat/Miss Upgrade
Return Since 0.34%
Last FQE 08/31/2022
Next FQE 11/30/2022

Profile

Edit
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
URL http://www.nurixtx.com
Investor Relations URL https://ir.nurixtx.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Jan. 27, 2023 (est.)
Last Earnings Release Oct. 06, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
--
--
--
-11.95%
-59.03%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-14.29%
-2.65%
-93.40%
-86.49%
-84.35%
-93.01%
35.12%
-4.82%
-56.96%
--
--
--
--
--
-7.30%
-46.37%
-36.11%
--
--
--
--
--
--
-40.58%
45.93%
--
--
--
--
--
--
-55.46%
-55.64%
As of November 25, 2022.

Profile

Edit
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
URL http://www.nurixtx.com
Investor Relations URL https://ir.nurixtx.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Jan. 27, 2023 (est.)
Last Earnings Release Oct. 06, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
ETCHX 14.62M USD 1.11%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter NRIX Tweets